Momenta Pharmaceuticals Announces Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2019
March 28 2019 - 07:00AM
Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology
company focused on discovering and developing novel biologic
therapeutics to treat rare immune-mediated diseases, today
announced the selection of new research for presentation at the
AACR Annual Meeting, being held March 29 – April 3, 2019 in
Atlanta, GA. This research demonstrates the potential of our Fc
multimerization technology to significantly enhance the potency and
efficacy of a variety of cell depleting therapeutic antibodies,
including antibodies targeting CD38 and CTLA-4.
“Therapeutics like Rituxan® and Darzalex®, which engage the Fc
gamma receptor and complement systems to mediate cell depletion,
are important standards-of-care for patients with cancer and
autoimmune disease. However, inefficent engagement limits efficacy
and, in many patients, contributes to drug resistance,” said Tony
Manning, Ph.D., Momenta’s chief scientific officer. “Importantly,
these posters featured at AACR demonstrate the potential of
Momenta’s Fc multimerization technology to maximize engagement of
the Fc gamma receptor and complement system, thereby enabling the
discovery of potentially best-in-class agents targeting CD38 and
CTLA-4. Further, this research reinforces our belief in the broad
applicability of our Fc multimerization platform to produce
enhanced therapeutic antibodies across a range of targets,
including for the treatment of cancer.”
Presentation Details:
Title: Discovery of a Potential Best-in-Class Anti-CD38
Therapeutic Utilizing Fc Multimerization (Session
PO.IM02.16 – Therapeutic Antibodies 1, Abstract
561/25)Date: March 31, 2019Time:
1:00 pm-5:00 pm ETLocation: Section 23, Georgia
World Conference Center, Atlanta |
Anti-CD38 monoclonal antibodies (mAbs) induce
tumor cell depletion in part by Fc-dependent effector mechanisms.
This presentation describes the discovery of a novel anti-CD38 Fc
multimer with superior efficacy and potency to existing anti-CD38
therapeutic antibodies in both cell systems and in non-human
primates, and also with the ability to efficiently deplete
Darzalex-resistant multiple myeloma patient tumor cells.
Title: Improved Fc-mediated Effector Functions By An
Anti-CTLA-4 Multivalent Fc Agent (Session PO.IM02.05 –
Immune Checkpoints 1, Abstract 3244 / 24)Date:
April 2, 2019Time: 8:00 am -12:00 pm
ETLocation: Section 24, Georgia World Conference
Center, Atlanta |
This presentation describes the discovery of a novel anti-CTLA-4
Fc multimer that maintains checkpoint blockade activity whilst
simultaneously enhancing the ability to deplete CTLA-4-expressing T
regulatory cells with immune-supressive activity. Such an agent has
potential to enhance anti-tumor activity through the dual
mechanisms of checkpoint blockade and Treg depletion.
Materials from both sessions will be available
for download following their formal presentation at: Momenta Events
and Presentations
About Momenta Momenta is a biotechnology
company with a validated innovative scientific platform focused on
discovering and developing novel therapeutics to treat rare,
immune-mediated diseases. Momenta’s product candidate, M281, is a
potentially best-in-class anti-FcRn antibody; M254, is a
hypersialylated human immunoglobulin (hsIgG) designed as a high
potency alternative to intravenous immunoglobulin (IVIg); and M230
(CSL730), is a potential first-in-class novel recombinant Fc
multimer being developed in collaboration with CSL. Momenta also
has a focused pipeline of two biosimilar candidates: M923,
Momenta’s wholly-owned proposed biosimilar to HUMIRA®, and M710, a
proposed biosimilar to EYLEA® being developed in collaboration
with Mylan. Momenta’s two FDA-approved complex generic
products, enoxaparin sodium injection and Glatopa® (glatiramer
acetate injection), are marketed by its collaboration
partner, Sandoz.
To learn more about Momenta, please
visit www.momentapharma.com, which does not form a part
of this press release. Momenta’s logo, trademarks, and service
marks are the property of Momenta Pharmaceuticals,
Inc. All other trade names, trademarks, or service marks are
property of their respective owners.
Forward-Looking Statements Statements in
this press release regarding management's future expectations,
beliefs, intentions, goals, strategies, plans or prospects, are
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, including but not limited
to statements about the design, timing and goals of clinical
trials, and the availability and timing of reporting results; the
use efficacy, safety, tolerability, convenience and commercial
potential of our product candidates, including their potential as
best-in-class agents and the potential actions and effects of our
product candidates. Forward-looking statements may be identified by
words such as "believe," "continue," “plan to”, "potential,"
"will," and other similar words or expressions, or the negative of
these words or similar words or expressions. Such forward-looking
statements involve known and unknown risks, uncertainties and other
important factors, including the risk of the unpredictable nature
of early stage development efforts for our product candidates;
safety, efficacy or tolerability problems with our product
candidates; unexpected adverse clinical trial results; and
those referred to under the section "Risk Factors" in the Company's
Annual Report on Form 10-K for the year ended December 31,
2018 filed with the Securities and Exchange Commission,
as well as other documents that may be filed by the Company from
time to time with the Securities and Exchange Commission. As a
result of such risks, uncertainties and factors, the Company's
actual results may differ materially from any future results,
performance or achievements discussed in or implied by the
forward-looking statements contained herein. The Company is
providing the information in this press release as of this date and
assumes no obligations to update the information included in this
press release or revise any forward-looking statements, whether as
a result of new information, future events or otherwise.
INVESTOR CONTACT: Patty
Eisenhaur Momenta Pharmaceuticals 1-617-395-5189
IR@momentapharma.com |
MEDIA CONTACT: Karen
Sharma MacDougall 1-781-235-3060 Momenta@macbiocom.com |
|
|
Momenta Pharmaceuticals (NASDAQ:MNTA)
Historical Stock Chart
From Feb 2024 to Mar 2024
Momenta Pharmaceuticals (NASDAQ:MNTA)
Historical Stock Chart
From Mar 2023 to Mar 2024